Perlmutter Cancer Center

The main purpose of this study is to determine the effectiveness of durvalumab in combination with other experimental drugs to the effectiveness of durvalumab when used alone by assessing tumor changes following therapy in the resected NSCLC lesions after resection. The study is also being done to evaluate the safety and tolerability of durvalumab when used alone and in combination with other experimental drugs in people with non-small cell lung cancer. The study will also evaluate how much of the study drug(s) is in your blood at various times, whether your immune system becomes activated to help control the cancer following treatment with the study drug(s) and whether your body produces antibodies against any of the study drugs as a response to the treatment. Further, this study will evaluate changes in microbiome (microorganisms in specific environment, in this case our body or part of the body) that are compared to clinical outcome of the durvalumab when used alone or in combination with other experimental drugs.